Atypical hemolytic uremic syndrome (aHUS) is a complement-mediated thrombotic microangiopathy (TMA) resulting from uncontrolled activation of the alternate complement pathway. It is necessary to distinguish a recurrent aHUS posttransplant from de novo aHUS, as the former is usually associated with complement abnormalities and has a poorer prognosis. Furthermore, COVID-19 is believed to unmask underlying complement defects triggering a relapse of aHUS. In this report, we present one such unique histologic presentation of recurrent TMA following a COVID-19 infection, which was not just a diagnostic challenge but could easily have been misdiagnosed as an antibody-mediated rejection.
No takes yet. Share an insight, caveat, or question.
Swain et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: